HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$4.90
Day range
$4.45 - $4.89
Year range
$2.71 - $5.10
Market cap
854.98M USD
Avg Volume
1.23M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 10.74M | 522.19% |
Operating expense | 8.45M | -61.55% |
Net income | 2.52M | 112.74% |
Net profit margin | 23.49 | 102.05% |
Earnings per share | 0.01 | 109.05% |
EBITDA | 1.92M | 109.15% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 98.09M | -30.92% |
Total assets | 103.27M | -35.48% |
Total liabilities | 20.29M | -46.02% |
Total equity | 82.98M | — |
Shares outstanding | 191.70M | — |
Price to book | 11.40 | — |
Return on assets | 4.34% | — |
Return on capital | 5.54% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 2.52M | 112.74% |
Cash from operations | -15.75M | -8.58% |
Cash from investing | 15.61M | 58.83% |
Cash from financing | 453.00K | -98.14% |
Net change in cash | 336.00K | -98.29% |
Free cash flow | -13.34M | -87.90% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
44
